NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"The methods for detecting the appropriate cancer cell protein from the lysate for a variety of cancers, including GBM (that patent was an outcome of the Regents agreement to write the IND and come up with GMP guidelines). "

Your saying they have patents on methods for isolating the neoantigens in the lysate? At the end of the Prins video, or in the questions after (the next video) Prins talks about the desire to do this, but he only spoke about T-Cell extraction, etc.. as far as I know.

It occurred to me when the topic of neoantigen isolation in the lysate came up, that this might be where Pyrrhonians DC pathway bottleneck shows it's head. There are so many self-antigens for every neoantigen, that the number of DC's required to address the undifferentiated bulk of antigens might overwhelm these DC travel pathways. According to Pyrrho's interpretation of the post analysis of one failed product, that is what they concluded was the primary problem.

If they could pick out only the neoantigens in the lysate then this issue would be much relaxed as would related crowding issues at the lymph nodes.

This past week I have been emailing Les my big ideas on how to possibly accomplish this isolation. Very likely a waste of his time. But you are saying that UCLA has methods already developed? Are you saying that DCVax-L already uses those methods?